{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464392155
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[Interleukin 6|IL6]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1194585-53-9
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| C=6450 | H=9926 | N=1690 | O=1998 | S=46
| molecular_weight = 144.6 kg/mol
| KEGG = D10080
}}

'''Sirukumab''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''CNTO-136''') is a human monoclonal antibody designed for the treatment of [[rheumatoid arthritis]].<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref> It acts against the proinflammatory cytokine [[Interleukin 6]] (IL-6).

Sirukumab is currently under [[drug development|development]] by [[Johnson & Johnson]]'s subsidiary [[Centocor]]<ref name=Ph2/>

==Clinical trials==
===Rheumatoid arthritis===
It has started clinical trials.<ref name=NCT00718718>[http://clinicaltrials.gov/ct2/show/NCT00718718 A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy], clinicaltrials.gov</ref> and reported some phase II results.<ref name=Ph2>[http://www.prnewswire.com/news-releases/interleukin-6-inhibitor-sirukumab-cnto-136-phase-2-data-show-promise-in-the-treatment-of-active-rheumatoid-arthritis-122579373.html Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis]</ref>

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.<ref name=G2015>[http://seekingalpha.com/news/2987756-glaxo-says-top-line-results-positive-in-late-stage-study-of-sirukumab-in-rheumatoid-arthritis Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015]</ref>
By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.<ref>[http://www.medpagetoday.com/mastery-of-medicine/rheumatology-mastery-in-ra/62753 IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab. Jan 2017]</ref>

===Other===
The drug is currently in [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for the treatment of [[depression (mood)|depression]].<ref>[http://adisinsight.springer.com/drugs/800026523 adisinsight ]
</ref>

==See also==
* [[Anti-IL-6]]
* [[List of investigational antidepressants]]

==References==
{{Reflist|2}}


{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Antidepressants]]
[[Category:Janssen Biotech]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}